As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...

Significantly longer progression-free survival seen with addition of palbociclib to maintenance anti-HER2 and endocrine therapies.

Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Experts discuss the small but promising study.

A plant-based compound called sulfuretin is being explored as a potential cancer treatment. Sulfuretin stopped the progression of cancer cells in a lab study. Researchers are doing additional testing ...

For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine ...